

**Supplementary Table 1.** Prevalence of susceptibility associated genotypes across datasets.

Dataset	PCN genotypes		TET genotypes	
	Susceptible	Non-susceptible	Susceptible	Non-susceptible
Alfsnes et al. 2020 <sup>1</sup>	18 (1.9%)	906 (98.1%)	222 (24.0%)	702 (76.0%)
Buckley et al. 2018 <sup>2</sup>	0 (0.0%)	93 (100.0%)	93 (100.0%)	0 (0.0%)
Cehovin et al. 2018 <sup>3</sup>	0 (0.0%)	103 (100.0%)	0 (0.0%)	103 (100.0%)
De Silva et al. 2016 <sup>4</sup>	35 (2.5%)	1365 (97.5%)	219 (15.6%)	1181 (84.4%)
Demczuk et al. 2015 <sup>5</sup>	7 (6.6%)	99 (93.4%)	20 (18.9%)	86 (81.1%)
Demczuk et al. 2016 <sup>6</sup>	3 (1.5%)	193 (98.5%)	1 (0.5%)	195 (99.5%)
Eyre et al. 2017 <sup>7</sup>	21 (9.1%)	210 (90.9%)	33 (14.3%)	198 (85.7%)
Ezewudo et al. 2015 <sup>8</sup>	3 (5.6%)	51 (94.4%)	8 (14.8%)	46 (85.2%)
Fifer et al. 2018 <sup>9</sup>	0 (0.0%)	50 (100.0%)	0 (0.0%)	50 (100.0%)
Grad et al. 2014, 2016 <sup>10,11</sup>	11 (1.0%)	1084 (99.0%)	56 (5.1%)	1039 (94.9%)
Harris et al. 2018 <sup>12</sup>	54 (5.3%)	960 (94.7%)	119 (11.7%)	895 (88.3%)
Kwong et al. 2017 <sup>13</sup>	0 (0.0%)	94 (100.0%)	2 (2.1%)	92 (97.9%)
Lan et al. 2020 <sup>14</sup>	2 (0.9%)	226 (99.1%)	2 (0.9%)	226 (99.1%)
Lee et al. 2018 <sup>15</sup>	4 (1.0%)	393 (99.0%)	119 (30.0%)	278 (70.0%)
Mortimer et al. 2020 <sup>16</sup>	34 (3.8%)	862 (96.2%)	129 (14.4%)	767 (85.6%)
Peng et al. 2019 <sup>17</sup>	0 (0.0%)	421 (100.0%)	0 (0.0%)	421 (100.0%)
Ryan et al. 2018 <sup>18</sup>	0 (0.0%)	39 (100.0%)	1 (2.6%)	38 (97.4%)
Sánchez-Busó et al. 2018 <sup>19</sup>	30 (7.9%)	348 (92.1%)	36 (9.5%)	342 (90.5%)
Thomas et al. 2019 <sup>20</sup>	7 (1.1%)	606 (98.9%)	59 (9.6%)	554 (90.4%)
Town et al. 2020 <sup>21</sup>	13 (1.0%)	1259 (99.0%)	257 (20.2%)	1016 (79.8%)
Williamson et al. 2019 <sup>22</sup>	6 (0.3%)	2175 (99.7%)	506 (23.2%)	1675 (76.8%)
Yahara et al. 2018 <sup>23</sup>	4 (1.5%)	256 (98.5%)	36 (13.8%)	224 (86.2%)

## References.

- 1 Alfsnes K, Eldholm V, Olsen AO, *et al.* Genomic epidemiology and population structure of *Neisseria gonorrhoeae* in Norway, 2016–2017. *Microbial Genomics* 2020. DOI:10.1099/mgen.0.000359.
- 2 Buckley C, Forde BM, Trembizki E, Lahra MM, Beatson SA, Whiley DM. Use of whole genome sequencing to investigate an increase in *Neisseria gonorrhoeae* infection among women in urban areas of Australia. *Scientific Reports* 2018; **8**: 1503.
- 3 Cehovin A, Harrison OB, Lewis SB, *et al.* Identification of Novel *Neisseria gonorrhoeae* Lineages Harboring Resistance Plasmids in Coastal Kenya. *J Infect Dis* 2018; **218**: 801–8.
- 4 De Silva D, Peters J, Cole K, *et al.* Whole-genome sequencing to determine transmission of *Neisseria gonorrhoeae*: an observational study. *The Lancet Infectious Diseases* 2016; **16**: 1295–303.
- 5 Demczuk W, Lynch T, Martin I, *et al.* Whole-Genome Phylogenomic Heterogeneity of *Neisseria gonorrhoeae* Isolates with Decreased Cephalosporin Susceptibility Collected in Canada between 1989 and 2013. *J Clin Microbiol* 2015; **53**: 191–200.
- 6 Demczuk W, Martin I, Peterson S, *et al.* Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant *Neisseria gonorrhoeae* in Canada from 1997 to 2014. *J Clin Microbiol* 2016; **54**: 1304–13.
- 7 Eyre DW, De Silva D, Cole K, *et al.* WGS to predict antibiotic MICs for *Neisseria gonorrhoeae*. *J Antimicrob Chemother* 2017; **72**: 1937–47.
- 8 Ezewudo MN, Joseph SJ, Castillo-Ramirez S, *et al.* Population structure of *Neisseria gonorrhoeae* based on whole genome data and its relationship with antibiotic resistance. *PeerJ* 2015; **3**: e806.
- 9 Fifer H, Cole M, Hughes G, *et al.* Sustained transmission of high-level azithromycin-resistant *Neisseria gonorrhoeae* in England: an observational study. *Lancet Infect Dis* 2018; **18**: 573–81.
- 10 Grad YH, Kirkcaldy RD, Trees D, *et al.* Genomic epidemiology of *Neisseria gonorrhoeae* with reduced susceptibility to cefixime in the USA: a retrospective observational study. *The Lancet Infectious Diseases* 2014; **14**: 220–6.
- 11 Grad YH, Harris SR, Kirkcaldy RD, *et al.* Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000–2013. *J Infect Dis* 2016; **214**: 1579–87.
- 12 Harris SR, Cole MJ, Spiteri G, *et al.* Public health surveillance of multidrug-resistant clones of *Neisseria gonorrhoeae* in Europe: a genomic survey. *The Lancet Infectious Diseases* 2018; **18**: 758–68.
- 13 Kwong JC, Chow EPF, Stevens K, *et al.* Whole-genome sequencing reveals transmission of gonococcal antibiotic resistance among men who have sex with men: an observational study. *Sex Transm Infect* 2017; : sextrans-2017-053287.
- 14 Lan PT, Golparian D, Ringlander J, Van Hung L, Van Thuong N, Unemo M. Genomic analysis and antimicrobial resistance of *Neisseria gonorrhoeae* isolates from Vietnam in 2011 and 2015–16. *J Antimicrob Chemother* DOI:10.1093/jac/dkaa040.
- 15 Lee RS, Seemann T, Heffernan H, *et al.* Genomic epidemiology and antimicrobial resistance of *Neisseria gonorrhoeae* in New Zealand. *J Antimicrob Chemother* 2018; **73**: 353–64.
- 16 Mortimer TD, Pathela P, Crawley A, *et al.* The distribution and spread of susceptible and resistant *Neisseria gonorrhoeae* across demographic groups in a major metropolitan center. *Clin Infect Dis* DOI:10.1093/cid/ciaa1229.

- 17 Peng J-P, Yin Y-P, Chen S-C, *et al.* A Whole-genome Sequencing Analysis of *Neisseria gonorrhoeae* Isolates in China: An Observational Study. *EClinicalMedicine* 2019; **7**: 47–54.
- 18 Ryan L, Golparian D, Fennelly N, *et al.* Antimicrobial resistance and molecular epidemiology using whole-genome sequencing of *Neisseria gonorrhoeae* in Ireland, 2014–2016: focus on extended-spectrum cephalosporins and azithromycin. *Eur J Clin Microbiol Infect Dis* 2018; **37**: 1661–72.
- 19 Sánchez-Busó L, Golparian D, Corander J, *et al.* The impact of antimicrobials on gonococcal evolution. *Nature Microbiology* 2019; **4**: 1941–50.
- 20 Thomas JC, Seby S, Abrams AJ, *et al.* Evidence of Recent Genomic Evolution in Gonococcal Strains with Decreased Susceptibility to Cephalosporins or Azithromycin in the United States, 2014-2016. *J Infect Dis* DOI:10.1093/infdis/jjz079.
- 21 Town K, Harris S, Sánchez-Busó L, *et al.* Genomic and Phenotypic Variability in *Neisseria gonorrhoeae* Antimicrobial Susceptibility, England - Volume 26, Number 3—March 2020 - Emerging Infectious Diseases journal - CDC. DOI:10.3201/eid2603.190732.
- 22 Williamson DA, Chow EPF, Gorrie CL, *et al.* Bridging of *Neisseria gonorrhoeae* lineages across sexual networks in the HIV pre-exposure prophylaxis era. *Nat Commun* 2019; **10**: 1–10.
- 23 Yahara K, Nakayama S-I, Shimuta K, *et al.* Genomic surveillance of *Neisseria gonorrhoeae* to investigate the distribution and evolution of antimicrobial-resistance determinants and lineages. *Microb Genom* 2018; **4**. DOI:10.1099/mgen.0.000205.